Nov 29 2023
Healthcare
Recent Research
hVIVO, Specialist in human challenge trials
Oct 11 2023
CVS Group, Full-year 2023 results
Sep 21 2023
Malin Corporation, H1 2023 results
Sep 6 2023
Ergomed, Recommended cash offer
Sep 4 2023
Meet your Healthcare Research team
CVS Group
Trading update ahead of AGM
CVS has issued a trading statement, covering the first four months of its H1 2024 to end-October, ahead of its AGM today. Revenue growth and the EBITDA margin are in line with...
hVIVO
Specialist in human challenge trials
We are re-initiating coverage of hVIVO (HVO) with an ‘Outperform’ rating and a price target of 29p per share. Our investment thesis hinges on the robust industry growth outlook. HVO...
Uniphar
H1 results plus ambitious new targets and a new divisional structure
Uniphar has reported H1 2023 results with strong growth in gross profit and expects to meet market expectations for FY2023. The company has announced an ambitious new target of...
Uniphar
H1 results and new medium-term targets could be a positive catalyst
Uniphar’s share price has drifted on low volume to levels that we consider to be very attractive. It will report its interim results on Thursday September 14th and will also announce new...
Uniphar
H1 trading statement reflects strong operating performance
Uniphar’s H1 trading statement confirms that the business is performing very well and that the company is likely to achieve around 15% growth in EBITDA this year. Rising interest...
Uniphar
AGM statement
Ahead of its AGM later this morning, Uniphar has issued a brief statement. It reviewed its strong performance in 2022, when EBITDA grew by 13.4% and, encouragingly, outlined that trading...
Ergomed
Robust performance in 2022
Ergomed has released detailed FY 22 results following its trading update on January 31st, reflecting strong revenue growth and stable service fee gross profit margins. Expansion in the...
CVS Group
H1 results show above forecast margins
CVS’ interim results had largely been announced with the trading statement in January and reflect the execution of its strategy in line with targets announced at the Capital Markets...
Malin Corporation
Updated intrinsic value and tender offer details
Malin has announced that its latest intrinsic value has increased to €10.07, 35% above yesterday’s closing price. The company has also published details of its tender offer, which will be...
CVS Group
H1 trading statement reflects strong growth and is in line with forecasts
In its H1 trading statement to December 31st, CVS has indicated that revenue and earnings growth are strong and in line with our H1 forecasts. The outlook for trading in FY2023 is...
